| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.PHARMTHERA.2010.01.006 |
| P698 | PubMed publication ID | 20122960 |
| P50 | author | Helmut Butzkueven | Q38800130 |
| P2093 | author name string | Trevor Kilpatrick | |
| Mark Marriott | |||
| Gary Egan | |||
| Melissa Gresle | |||
| Scott Kolbe | |||
| Anneke Van der Walt | |||
| Estella Alexandrou | |||
| P433 | issue | 1 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 82-93 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Pharmacology & Therapeutics | Q3378596 |
| P1476 | title | Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade | |
| P478 | volume | 126 |
| Q34094705 | Bushen Yisui Capsule ameliorates axonal injury in experimental autoimmune encephalomyelitis. |
| Q38782456 | Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis |
| Q46078160 | Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis. |
| Q35937668 | Effect of Bushen Yisui Capsule () on oligodendrocyte lineage genes 1 and 2 in mice with experimental autoimmune encephalomyelitis |
| Q49834512 | Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review. |
| Q37559970 | Emerging immunopharmacological targets in multiple sclerosis |
| Q35954062 | Estrogen treatment prevents gray matter atrophy in experimental autoimmune encephalomyelitis |
| Q51400507 | Functional and molecular evidence of myelin- and neuroprotection by thyroid hormone administration in experimental allergic encephalomyelitis. |
| Q33568213 | Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis. |
| Q48895143 | Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist |
| Q37799890 | Inflammation and gliosis in neurological diseases – clinical implications |
| Q47677846 | Multiple Sclerosis: Basic and Clinical. |
| Q46406182 | Multiple sclerosis: An old drug plays a new trick |
| Q37979969 | Multiple sclerosis: neuroprotective alliance of estrogen-progesterone and gender |
| Q34389528 | New approaches in the management of multiple sclerosis |
| Q30479247 | Oestrogen receptor β ligand: a novel treatment to enhance endogenous functional remyelination |
| Q35080681 | Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes |
| Q36821577 | Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis |
| Q37699846 | Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment |
| Q26862803 | Promoting myelin repair and return of function in multiple sclerosis |
| Q37172150 | Serial Diffusion Tensor Imaging of the Optic Radiations after Acute Optic Neuritis. |
| Q37876955 | Sex steroids control neuroinflammatory processes in the brain: relevance for acute ischaemia and degenerative demyelination |
| Q34101974 | Stage-specific regulation of oligodendrocyte development by Wnt/β-catenin signaling |
| Q34782075 | Targeting oligodendrocyte protection and remyelination in multiple sclerosis |
| Q64941831 | The Beneficial Effect of Human Amnion Mesenchymal Cells in Inhibition of Inflammation and Induction of Neuronal Repair in EAE Mice. |
| Q34468304 | The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. |
| Q33721200 | Thirteen compounds promoting oligodendrocyte progenitor cell differentiation and remyelination for treating multiple sclerosis: WO2010054307 |
| Q37071396 | Thyroid hormone alleviates demyelination induced by cuprizone through its role in remyelination during the remission period |
| Q44629714 | Undifferentiated MSCs are able to myelinate DRG neuron processes through p75. |
Search more.